Zimmer Biomet (NYSE:ZBH) Updates FY 2026 Earnings Guidance

Posted by Francis Steltz on Aug 5th, 2026

Zimmer Biomet (NYSE:ZBH – Get Free Report) updated its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 8.470-8.590 for the period, compared to the consensus EPS estimate of 8.480. The company issued revenue guidance of $8.6 billion-$8.6 billion, compared to the consensus revenue estimate of $8.5 billion.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $96.02 on Wednesday. The company’s fifty day moving average is $89.30 and its two-hundred day moving average is $89.95. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. Zimmer Biomet has a 12-month low of $79.12 and a 12-month high of $108.29. The company has a market cap of $18.58 billion, a P/E ratio of 24.94, a price-to-earnings-growth ratio of 2.86 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last issued its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities analysts expect that Zimmer Biomet will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Investors of record on Thursday, June 25th were issued a $0.24 dividend. The ex-dividend date was Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Analysts Set New Price Targets

ZBH has been the topic of several analyst reports. Wells Fargo & Company lowered their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 29th. Leerink Partners initiated coverage on Zimmer Biomet in a research report on Monday, April 13th. They issued a “hold” rating and a $101.00 price target for the company. Zacks Research downgraded Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research note on Monday, July 27th. Weiss Ratings lowered Zimmer Biomet from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, July 20th. Finally, Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, July 25th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, twelve have given a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $102.00.

Get Our Latest Analysis on ZBH

Insider Activity at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.28% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zimmer Biomet

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its stake in Zimmer Biomet by 276.6% during the second quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock worth $118,627,000 after buying an additional 955,284 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Zimmer Biomet by 28.6% during the 4th quarter. Victory Capital Management Inc. now owns 2,475,768 shares of the medical equipment provider’s stock worth $223,529,000 after acquiring an additional 551,005 shares during the period. Schonfeld Strategic Advisors LLC lifted its holdings in shares of Zimmer Biomet by 3,633.7% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 464,250 shares of the medical equipment provider’s stock worth $45,729,000 after acquiring an additional 451,816 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Zimmer Biomet by 30.5% during the 4th quarter. The Manufacturers Life Insurance Company now owns 1,544,646 shares of the medical equipment provider’s stock valued at $139,054,000 after acquiring an additional 360,624 shares in the last quarter. Finally, Invesco Ltd. increased its stake in Zimmer Biomet by 10.6% in the fourth quarter. Invesco Ltd. now owns 3,361,075 shares of the medical equipment provider’s stock valued at $302,228,000 after acquiring an additional 322,689 shares during the period. 88.89% of the stock is currently owned by institutional investors.

About Zimmer Biomet

(Get Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.